| They are well positioned in the rapidly emerging inflammasome space with a highly differentiated monoclonal antibody, Inflammasome ASC Inhibitor IC 100, and in kidney disease with phase 2 Cholesterol Efflux MediatorTM VAR 200.
The lead indication for IC 100 is obesity with metabolic complications, and for VAR 200, focal segmental glomerulosclerosis (FSGS).
Each therapeutic area offers a “pipeline within a product,” with potential for numerous indications.
Grab Sources: ZVSA Presentation. -----
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is at the top spot on my watchlist Friday.
I'll be in touch with updates when necessary. Talk again shortly.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, a single member limited liability company. Data is provided from third-party sources and MarketPulseToday is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Thousand Sun Media LLC has not been compensated for the January 9th and 10th, 2025's profile on (ZVSA:US).
Neither Thousand Sun Media LLC or its member own shares of (ZVSA:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ | 
ليست هناك تعليقات:
إرسال تعليق